Clinical trials: Interstitial Cystitis, Chronic
Interstitial Cystitis
A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome
The primary objective of the study is to evaluate the efficacy of fremanezumab in reducing pain in patients with interstitial cystitis-bladder pain syndrome (IC-BPS).
- Trial name
- NCT04447729
- Testing
- fremanezumab
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Interstitial Cystitis, Painful Bladder Syndrome
OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)
The study compares the analgesic efficacy of OXN PR vs placebo in opioid-naive subjects suffering from severe pain due to Bladder Pain Syndrome.
- Conditions
- Interstitial Cystitis, Painful Bladder Syndrome, Pain
- Trial name
- NCT01197261
- Testing
- Oxycodone naloxone prolonged release tablets
- Where
- 5 sites in Czechia, Germany and 3 more
- Volunteers
- 120 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Cystitis, Interstitial
An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis
The purpose of this study is to determine whether PF-04383119 is effective in the treatment of pain associated with interstitial cystitis.
- Trial name
- NCT00601484
- Testing
- PF-04383119
- Where
- 34 sites in United States
- Volunteers
- 65 people
- Sponsor
- Pfizer
Cystitis, Interstitial, Urologic Diseases
A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain
The purpose of this study is to evaluate the analgesic efficacy, safety, and tolerability of JNJ-42160443 compared to placebo in patients with moderate to severe, chronic bladder pain from interstitial cystitis and/or painful…
- Conditions
- Cystitis, Interstitial, Urologic Diseases, Urinary Bladder Diseases, Cystitis
- Trial name
- NCT01060254
- Testing
- JNJ-42160443
- Where
- 25 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Interstitial Cystitis
Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis
The purpose of this study is to determine if LiRIS®, an investigational drug-delivery system, is safe, tolerable and effective in women with Interstitial Cystitis.
- Trial name
- NCT01475253
- Testing
- Lidocaine Releasing Intravesical System - LiRIS®
- Where
- 29 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- Allergan
Healthy
Safety and Tolerability Study of the Taris Placebo System
The aim of this protocol is to evaluate the tolerability of the Taris placebo system for the development program and to provide key safety and tolerability data for the Taris platform.
- Trial name
- NCT01051336
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- TARIS Biomedical, Inc.